- Home
- EDF vs LXRX Comparison
EDF vs LXRX Comparison
Compare EDF & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- LXRX
- Stock Information
- Founded
- EDF 2010
- LXRX 1995
- Country
- EDF United States
- LXRX United States
- Employees
- EDF N/A
- LXRX N/A
- Industry
- EDF Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- LXRX Health Care
- Exchange
- EDF Nasdaq
- LXRX Nasdaq
- Market Cap
- EDF 148.8M
- LXRX 124.4M
- IPO Year
- EDF N/A
- LXRX 2000
- Fundamental
- Price
- EDF $4.68
- LXRX $0.51
- Analyst Decision
- EDF
- LXRX Buy
- Analyst Count
- EDF 0
- LXRX 4
- Target Price
- EDF N/A
- LXRX $3.67
- AVG Volume (30 Days)
- EDF 160.6K
- LXRX 32.2M
- Earning Date
- EDF 01-01-0001
- LXRX 05-01-2025
- Dividend Yield
- EDF 13.14%
- LXRX N/A
- EPS Growth
- EDF N/A
- LXRX N/A
- EPS
- EDF N/A
- LXRX N/A
- Revenue
- EDF N/A
- LXRX $31,081,000.00
- Revenue This Year
- EDF N/A
- LXRX N/A
- Revenue Next Year
- EDF N/A
- LXRX $63.36
- P/E Ratio
- EDF N/A
- LXRX N/A
- Revenue Growth
- EDF N/A
- LXRX 2481.48
- 52 Week Low
- EDF $3.51
- LXRX $0.28
- 52 Week High
- EDF $5.50
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- EDF 46.64
- LXRX 53.30
- Support Level
- EDF $4.22
- LXRX $0.48
- Resistance Level
- EDF $5.09
- LXRX $0.60
- Average True Range (ATR)
- EDF 0.15
- LXRX 0.09
- MACD
- EDF -0.00
- LXRX 0.01
- Stochastic Oscillator
- EDF 56.84
- LXRX 42.86
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.